ClinicalTrials.gg
CompletedNCT06022211Updated Oct 19, 2026

ANRS0268s POSTCOVIET

An observational study in Post COVID-19 Condition, sponsored by ANRS, Emerging Infectious Diseases. Completed at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by ANRS, Emerging Infectious Diseases · Observational

How we know

Updated Oct 19, 2026Now CompletedFirst site in Vietnam+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
807
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases — 3 open to participants now, 5 under way, none of them phase 3. COVID-19 · ANRS, Emerging Infectious Diseases.

Started
2024
with 1 other
Observational
6 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases, this one is one of 2 that started in 2024, is one of 6 observational ones, and was the 12th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the prevalence of the post-COVID-19 condition in confirmed mild, moderate, and severe COVID-19 adult patients in Hai Phong, Vietnam.

Read the detailed description

It is a cross-sectional study implemented in Hai Phong (Vietnam) by the Infectious and Tropical Diseases Department of Viet Tiep 2 hospital and the Department of Public Health of the Hai Phong University of Medicine and Pharmacy (HPMU).

The aim is to enroll moderate and severe COVID-19 patients from the 2 following provincial hospitals, Viet Tiep hospital and Kien An hospital, and mild COVID-19 patients from the community level in Hai Phong to assess the burden of post-COVID-19 condition in each patient group (mild, moderate or severe acute COVID-19).

835 participants are aimed to be interviewed through phone calls: 196 participants with mild disease, 289 participants with moderate disease, and 350 participants with severe disease. In case of suspected post-COVID-19 condition, the participant will be proposed to come to Viet Tiep 2 hospital for a study visit i) to confirm the post-COVID-19 condition, ii) to describe symptoms, iii) to evaluate the functional limitations related to the post-COVID-19 condition, and iv) to assess the determinants of the post-COVID-19 condition in patients with mild, moderate, and severe acute COVID-19.

03

Conditions studied

  • Post COVID-19 Condition

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients hospitalised in Viet Tiep 2 hospital or Kien An hospital for moderate or severe acute COVID-19 3 to 12 months before inclusion, or registered in the provincial CDC database for mild COVID-19 that occurred 3-12 months before inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or more;
  • With a history of documented COVID-19 as confirmed by either a positive SARS-CoV-2 RT-PCR or antigenic test, 3-12 months before inclusion;
  • Hospitalised in Viet Tiep 2 hospital or Kien An hospital (tertiary care hospitals) with moderate or severe COVID-19 or registered in provincial CDC health system for mild COVID-19;
  • Accepting to participate in the study;

Exclusion criteria

Exclusion Criteria:

  • Not able to understand or answer a quick phone questionnaire;
  • Individuals who refuse or cannot come to Viet Tiep 2 hospital in case of the suspected post-COVID-19 condition.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
807 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. The primary endpoint is the proportion of participants who present a post-COVID-19 condition in adult patients with confirmed mild, moderate, and severe COVID-19 in Hai Phong, Vietnam.

    According to the WHO definition

    Time frame: Day 0

Secondary outcomes

  1. Type and frequency of symptoms of the post-COVID-19 condition.

    Time frame: Day 0

  2. Functional limitations among participants with the post-COVID-19 condition.

    Time frame: Day 0

  3. Factors related to occurrence of post-COVID-19 condition in adults after mild, moderate, and severe acute COVID-19.

    Time frame: Day 0

07

Study locations

1 site
  • Hôpital Viet Tiep 2
    Haiphong, Hải Phòng, Vietnam
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Feb 2025, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Dec 2023 → Mar 2024, primary completion May 2024 → Feb 2025 and completion Dec 2024 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 1, 2023
StartActual
Mar 27, 2024was Dec 2023
Primary completionActual
Feb 28, 2025was May 2024
CompletionActual
Feb 28, 2025was Dec 2024
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 19, 2026
Sites
1 site added — first site in Vietnam
Show site
  • Hôpital Viet Tiep 2 · Haiphong, Vietnam
Oct 19, 2026
Start date
Dec 2023→Mar 27, 2024 (actual)
Oct 19, 2026
Primary completion
May 2024→Feb 28, 2025 (actual)
Oct 19, 2026
Study completion
Dec 2024→Feb 28, 2025 (actual)
Oct 19, 2026
Enrollment
835 (estimated)→807 (actual)
Oct 19, 2026
Title
Post-COVID-19 Condition: Observational Study in Vietnam→ANRS0268s POSTCOVIET
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Completed
    1 site added — first site in Vietnam
    Show site
    • Hôpital Viet Tiep 2 · Haiphong, Vietnam
    Start date Dec 2023→Mar 27, 2024 (now actual)
    Primary completion May 2024→Feb 28, 2025 (now actual)
    Study completion Dec 2024→Feb 28, 2025 (now actual)
    Enrollment 835 (estimated)→807 (actual)
    Title Post-COVID-19 Condition: Observational Study in Vietnam→ANRS0268s POSTCOVIET
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06022211
Responsible party
Sponsor
First posted
Sep 1, 2023
Start date
Mar 27, 2024
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion